| Cat.No. | Name | Information |
|---|---|---|
| M1721 | AZD4547 | AZD4547 (Fexagratinib) is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
| M10048 | PF-05231023 | PF-05231023 is an FGF21-receptor agonist, it is also a potential treatment for T2DM. |
| M1875 | PD173074 | PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. |
| M28863 | PD-089828 | PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity. |
| M28710 | E7090 | E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively. |
| M24907 | Pegbelfermin | Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH). |
| M24606 | Vofatamab | Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
| M20223 | WAY-625530 | WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor. |
| M20221 | WAY-621856 | WAY-621856 is a FGFR inhibitor. |
| M20193 | WAY-603814 | WAY-603814 is a FGFR1 inhibitor |
| M20183 | WAY-600868 | WAY-600868 is a FGFR3 inhibitor. |
| M20165 | WAY-353890 | WAY-353890 is a inhibitor of protein kinase FGFR1 |
| M20050 | WAY-272449 | WAY-272449 is a FGFR1 inhibitor. |
| M20048 | WAY-272130 | WAY-272130 is a FGFR1 inhibitor. |
| M20039 | WAY-270599 | WAY-270599 is a FGFR1 inhibitor |
| M14894 | Ferulic acid sodium | Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
